Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Clinical trial NCT03564340 · RECRUITING

Trial details

NCT number: NCT03564340
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cancer Recurrent Endometrial Cancer Endometrial Cancer Low-grade Serous Ovarian Cancer

Start date: 2018-05-21
Primary completion: 2027-05-10
Enrollment: 890

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.